Corcept Therapeutics (CORT) return on equity (ROE)

Return on equity · fiscal 2025
15.4%

Corcept Therapeutics (CORT) earned a return on equity of 15.4% in fiscal 2025 (the year ended December 31, 2025). That is 5.4 percentage points lower than the 20.8% of fiscal 2024. Figures as of 17 Nov 2026, 19:55 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
15.4%
Change on fiscal 2024
−5.4 pts
Highest on record
67.6%fiscal 2017
Lowest on record
-391.1%fiscal 2006
Fiscal years on record
212004–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Corcept Therapeutics return on equity (ROE), in more detail

Across the 21 fiscal years on record (2004–2025), the highest was 67.6% in fiscal 2017 and the lowest -391.1% in fiscal 2006. The fiscal 2025 figure is higher than in 55% of the 20 earlier fiscal years on record, whose median is -34.2%.

History · 21 fiscal years

Return on equity by fiscal year

Corcept Therapeutics return on equity (ROE), year by year

Corcept Therapeutics (CORT) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202515.4% 5.4 pts down
202420.8% 0.2 pts down
202320.9% 0.7 pts up
202220.2% 9.7 pts down
202129.9% 9.7 pts up
202020.3% 5.1 pts down
201925.4% 2.0 pts down
201827.3% 40.3 pts down
201767.6% 47.9 pts up
201619.7% 54.3 pts up
2015-34.6%—
2013-218.9% 157.3 pts down
2012-61.6% 31.4 pts up
2011-93.0% 29.3 pts up
2010-122.2% 30.9 pts down
2009-91.3% 27.4 pts up
2008-118.7% 40.1 pts down
2007-78.5% 312.5 pts up
2006-391.1% 315.5 pts down
2005-75.6% 41.7 pts down
2004-33.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Corcept Therapeutics and comparable companies
CompanyReturn on equityFiscal year
10x Genomics TXG-5.5%2025
HealthEquity HQY10.2%2026
Corcept Therapeutics CORT15.4%2025
Rhythm Pharmaceuticals RYTM-72.8%2025
Alkermes ALKS13.3%2025
PACS Group PACS20.2%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CORT

Corcept Therapeutics, figure by figure

Corcept Therapeutics (CORT) overview: price, valuation and scorecardAll health care companies by market value

Corcept Therapeutics return on equity (ROE): questions and answers

What is Corcept Therapeutics's return on equity?

Corcept Therapeutics (CORT) earned a return on equity of 15.4% in fiscal 2025 (the year ended December 31, 2025). That is 5.4 percentage points lower than the 20.8% of fiscal 2024.

Is Corcept Therapeutics's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 55% of the 20 earlier fiscal years on record, whose median is -34.2%.

What are the highest and lowest return on equity figures on record for Corcept Therapeutics?

Across the 21 fiscal years on record (2004–2025), the highest was 67.6% in fiscal 2017 and the lowest -391.1% in fiscal 2006.

How is Corcept Therapeutics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Corcept Therapeutics (CORT) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/CORT/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.